Structural Basis for Immunization With Postfusion Respiratory Syncytial Virus Fusion F Glycoprotein (RSV F) to Elicit High Neutralizing Antibody Titers

Respiratory syncytial virus (RSV) vaccine candidates based on a chief RSV neutralization antigen, the fusion (F) glycoprotein, have foundered due to problems with stability, purity, reproducibility, and potency. The authors of this article, published in the Proceedings of the National Academy of Sciences, have determined the crystal structure of an RSV F postfusion antigen that was structurally engineered for easy purification, homogeneity, and stability. Their approach to antigen design for a candidate RSV vaccine provides a model for optimizing and evaluating new vaccine antigens to address unmet needs.

Author(s): Swanson KA, Settembre EC, Shaw CA, et al.

Published: 2011

  • Download file (English)

    1 MB PDF (Located at www.pnas.org)

    Citation: Swanson KA, Settembre EC, Shaw CA, et al. Structural Basis for Immunization With Postfusion Respiratory Syncytial Virus Fusion F Glycoprotein (RSV F) to Elicit High Neutralizing Antibody Titers. Proceedings of the National Academy of Sciences. 2011;108(23)9619-9624.